Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
7.21
+0.40 (5.87%)
Aug 14, 2025, 11:25 AM - Market open
MRSN's stock price has decreased by -78.19% in the past year and price targets may not have had time to catch up.
Mersana Therapeutics Analyst Ratings
Total Analysts
4
Consensus Rating
Strong Buy
Price Target
$135.00
Upside
+1,772.40%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $125 → $30 | Strong Buy | Maintains | $125 → $30 | +316.09% | Aug 14, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $225 → $250 | Strong Buy | Maintains | $225 → $250 | +3,367.41% | May 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $125 | Strong Buy | Reiterates | $125 | +1,633.70% | May 16, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $150 → $125 | Strong Buy | Maintains | $150 → $125 | +1,633.70% | Aug 27, 2024 |
| Baird | Baird | Hold Maintains $100 → $75 | Hold | Maintains | $100 → $75 | +940.22% | Aug 14, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $125 | Sell → Hold | Upgrades | $125 | +1,633.70% | Mar 19, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades $50 → $175 | Hold → Buy | Upgrades | $50 → $175 | +2,327.18% | Feb 29, 2024 |
| Truist Securities | Truist Securities | Hold → Strong Buy Upgrades $225 | Hold → Strong Buy | Upgrades | $225 | +3,020.67% | Feb 29, 2024 |
| Baird | Baird | Hold Maintains $25 → $125 | Hold | Maintains | $25 → $125 | +1,633.70% | Feb 29, 2024 |
| Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $175 | Hold → Strong Buy | Upgrades | $175 | +2,327.18% | Feb 29, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $25 → $125 | Hold → Strong Buy | Upgrades | $25 → $125 | +1,633.70% | Dec 4, 2023 |
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $250 → $25 | Strong Buy → Hold | Downgrades | $250 → $25 | +246.74% | Jul 28, 2023 |
| Baird | Baird | Buy → Hold Downgrades $175 → $25 | Buy → Hold | Downgrades | $175 → $25 | +246.74% | Jul 28, 2023 |
| Wedbush | Wedbush | Buy → Hold Downgrades $300 → $50 | Buy → Hold | Downgrades | $300 → $50 | +593.48% | Jul 27, 2023 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 27, 2023 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.